سعر ايماتيب 100 مجم 10 كبسولات 2022

Imatinib 100 mg oral capsules (pack of 10), a tyrosine kinase inhibitor anticancer medicine.

• Most frequently reported adverse reactions (>=30%): edema, nausea, vomiting, muscle cramps, musculoskeletal pain, diarrhea, rash, fatigue and abdominal pain.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• The US Gleevec label lists no contraindications.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Edema and occasionally severe fluid retention (pleural or pericardial effusion, pulmonary edema, ascites) occur; weigh patients regularly and investigate unexpected rapid weight gain.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Anemia, neutropenia and thrombocytopenia occur and are managed with dose reduction, interruption or discontinuation.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Severe congestive heart failure and left ventricular dysfunction have been reported, particularly in patients with comorbidities or cardiac risk factors.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Severe hepatotoxicity, including fatalities, may occur.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Grade 3/4 hemorrhage and gastrointestinal perforation (some fatal) have been reported.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Bullous skin reactions (e.g. erythema multiforme, Stevens-Johnson syndrome), tumor lysis syndrome, hypothyroidism in thyroidectomy patients on levothyroxine, growth retardation in children and declining renal function have been reported.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Can cause fetal harm; females should use effective contraception. Motor vehicle accidents have been reported, so patients should be cautioned about driving or operating machinery.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Strong CYP3A4 inducersMay reduce imatinib exposure; consider alternative agents.DailyMed (U.S. National Library of Medicine)
• Strong CYP3A4 inhibitors; grapefruit juiceMay significantly increase imatinib exposure; avoid grapefruit juice.DailyMed (U.S. National Library of Medicine)
• CYP3A4 and CYP2D6 substrates with a narrow therapeutic windowImatinib inhibits CYP3A4 and CYP2D6 and may increase their concentrations; use with caution.DailyMed (U.S. National Library of Medicine)
• WarfarinPatients needing anticoagulation should receive low-molecular-weight or standard heparin instead of warfarin.DailyMed (U.S. National Library of Medicine)
• High-dose methotrexate (>500 mg/m2)Imatinib may delay methotrexate clearance.DailyMed (U.S. National Library of Medicine)

• Can cause fetal harm based on human and animal data; postmarketing reports include spontaneous abortions and congenital anomalies. Women should avoid pregnancy during treatment.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Imatinib and its active metabolite are excreted in human milk; do not breastfeed during treatment and for 1 month after the last dose.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Complete blood counts weekly for the first month, every 2 weeks for the second month, then periodically (e.g. every 2 to 3 months).General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Liver function before starting treatment and monthly thereafter or as clinically indicated; renal function at baseline and during therapy; body weight regularly; TSH in thyroidectomy patients on levothyroxine.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Imatinib: Inhibits multiple tyrosine kinases including BCR-ABL, the PDGF receptor and the stem cell factor receptor (c-Kit).